Page last updated: 2024-11-05

2h-benzo(a)quinolizin-2-ol, 2-ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-: Proposed catecholamine depletor. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9345
CHEMBL ID213814
SCHEMBL ID11790429
MeSH IDM0019226

Synonyms (28)

Synonym
OPREA1_578571 ,
2h-benzo(a)quinolizin-2-ol, 2-ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-
brn 1547216
ro 4-1284
2h-benzo(a)quinolizin-2-ol, 2-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-
ro 4-12884
ro-4-1284
bdbm50192902
2-ethyl-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-ol
CHEMBL213814 ,
ro-41284
2-ethyl-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-ol
unii-h2s3m5m720
h2s3m5m720 ,
303-75-3
5-21-05-00558 (beilstein handbook reference)
2-hydroxy-2-ethyl-3-isobutyl-9,10-dimethoxy-1,2,3,4,5,6,7-hexahydrobenzo[a]chinolizine
2-ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-2h-benzo(a)quinolizin-2-ol
2-hydroxy-2-ethyl-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine
SCHEMBL11790429
ro 4-1284, >=98% (hplc)
J-017934
NCGC00408863-01
2-ethyl-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizine-2-ol
Q27279565
2-ethyl-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol
DTXSID90952665
2h-benzo[a]quinolizin-2-ol, 2-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" However, severe toxic manifestations, including death, were elicited in the rat at 820 mg/kg and in the dog at 160 mg/kg."( A subchronic study of the toxicity of an orally administered benzoquinolizinyl derivative in the rat and dog.
Fonseca, EH; Hartnagel, RE; Kowalski, RL; Kraus, PJ; Phillips, BM, 1975
)
0.25
" This suggested a predominantly central site for the toxic interaction."( Synergism of the toxicity of physostigmine and neostigmine by lithium or by a reserpine-like agent (Ro4-1284).
Davis, WM; Hatoum, NS, 1980
)
0.26
" These findings provide evidence for a substantial accumulation of MPP(+) in VMAT2-containing vesicles in vivo in the rat striatum and support the hypothesis that MPP(+) sequestration in vesicles can provide protection against its toxic actions."( Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
Sonsalla, PK; Staal, RG, 2000
)
0.31

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Higher dosage (25 mg."( [Electrophysiological study of tianeptine, a new enhancer of serotonin uptake with antidepressant activity].
Lejeune, F; Poignant, JC; Reure, H, 1988
)
0.27
" A non-anorectic dosage of L110-140 (3."( The role of norepinephrine in feeding behavior.
Davies, RF; Panksepp, J; Rossi, J; Zolovick, AJ, 1982
)
0.26
") evoked dose-dependent shifts to the right of the dose-response curves to B-HT 933 whilst having minimal effects on the methoxamine dose-response curve."( An investigation into the selectivity of a novel series of benzoquinolizines for alpha 2-adrenoceptors in vivo.
Paciorek, PM; Pierce, V; Shepperson, NB; Waterfall, JF, 1984
)
0.27
" This confirms a previous report of a lethal synergism of physostigmine after subacute dosing with lithium."( Synergism of the toxicity of physostigmine and neostigmine by lithium or by a reserpine-like agent (Ro4-1284).
Davis, WM; Hatoum, NS, 1980
)
0.26
" Dose-response curves for striatally infused MPP(+) were determined in animals pretreated with or without a VMAT2 inhibitor."( Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
Sonsalla, PK; Staal, RG, 2000
)
0.31
" Current studies focused on the effects of co- and/or postinhibition of VMAT2 on the acute and chronic effects of MDMA and on the dose-response relationship between MDMA-induced elevations in body temperature and subsequent reductions in indolamine concentrations."( Concurrent Inhibition of Vesicular Monoamine Transporter 2 Does Not Protect Against 3,4-Methylenedioxymethamphetamine (Ecstasy) Induced Neurotoxicity.
Cholanians, AB; Lau, SS; Monks, TJ; Phan, AV, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 2D6Homo sapiens (human)Potency0.84870.00108.379861.1304AID1645840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki10.00000.00000.385510.0000AID1387457
Synaptic vesicular amine transporterRattus norvegicus (Norway rat)IC50 (µMol)0.50000.00100.01460.1000AID1770282
Synaptic vesicular amine transporterRattus norvegicus (Norway rat)Ki0.02800.00101.30096.2600AID271310
Synaptic vesicular amine transporterHomo sapiens (human)IC50 (µMol)0.15400.01320.48594.2000AID1387455
Synaptic vesicular amine transporterHomo sapiens (human)Ki0.69300.00530.83242.7600AID1387446; AID1387447; AID1387454
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (57)

Processvia Protein(s)Taxonomy
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to amphetamineSynaptic vesicular amine transporterHomo sapiens (human)
serotonin secretion by mast cellSynaptic vesicular amine transporterHomo sapiens (human)
histamine secretion by mast cellSynaptic vesicular amine transporterHomo sapiens (human)
neurotransmitter transportSynaptic vesicular amine transporterHomo sapiens (human)
chemical synaptic transmissionSynaptic vesicular amine transporterHomo sapiens (human)
locomotory behaviorSynaptic vesicular amine transporterHomo sapiens (human)
response to toxic substanceSynaptic vesicular amine transporterHomo sapiens (human)
post-embryonic developmentSynaptic vesicular amine transporterHomo sapiens (human)
monoamine transportSynaptic vesicular amine transporterHomo sapiens (human)
dopamine transportSynaptic vesicular amine transporterHomo sapiens (human)
sequestering of neurotransmitterSynaptic vesicular amine transporterHomo sapiens (human)
serotonin uptakeSynaptic vesicular amine transporterHomo sapiens (human)
histamine uptakeSynaptic vesicular amine transporterHomo sapiens (human)
neurotransmitter loading into synaptic vesicleSynaptic vesicular amine transporterHomo sapiens (human)
somato-dendritic dopamine secretionSynaptic vesicular amine transporterHomo sapiens (human)
proton transmembrane transportSynaptic vesicular amine transporterHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processSynaptic vesicular amine transporterHomo sapiens (human)
aminergic neurotransmitter loading into synaptic vesicleSynaptic vesicular amine transporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein bindingSynaptic vesicular amine transporterHomo sapiens (human)
monoamine transmembrane transporter activitySynaptic vesicular amine transporterHomo sapiens (human)
monoamine:proton antiporter activitySynaptic vesicular amine transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySynaptic vesicular amine transporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
centrosomeSynaptic vesicular amine transporterHomo sapiens (human)
plasma membraneSynaptic vesicular amine transporterHomo sapiens (human)
synaptic vesicleSynaptic vesicular amine transporterHomo sapiens (human)
membraneSynaptic vesicular amine transporterHomo sapiens (human)
axonSynaptic vesicular amine transporterHomo sapiens (human)
dendriteSynaptic vesicular amine transporterHomo sapiens (human)
secretory granule membraneSynaptic vesicular amine transporterHomo sapiens (human)
synaptic vesicle membraneSynaptic vesicular amine transporterHomo sapiens (human)
intracellular membrane-bounded organelleSynaptic vesicular amine transporterHomo sapiens (human)
clathrin-sculpted monoamine transport vesicle membraneSynaptic vesicular amine transporterHomo sapiens (human)
dopaminergic synapseSynaptic vesicular amine transporterHomo sapiens (human)
terminal boutonSynaptic vesicular amine transporterHomo sapiens (human)
synaptic vesicle membraneSynaptic vesicular amine transporterHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1387446Displacement of [3H]reserpine from human VMAT2 expressed in HEK293 cell membranes incubated for 60 mins by scintillation counting method2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID1387447Displacement of [3H]DHTB from human VMAT2 expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting method2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID1770282Inhibition of [3H]DTBZ binding to VMAT2 in rat brain incubated for 30 mins by liquid scintillation spectrometry analysis2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors.
AID1770285Inhibition of [3H]DA uptake at VMAT2 in rat striatal synaptosome incubated for 10 mins followed by [3H]DA addition and measured after 20 mins by TopCount scintillation counting method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors.
AID271310Inhibition of [3H]DTBZ binding to VMAT2 in rat synaptic vesicle membrane2006Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19
Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters.
AID1387456Inhibition of VMAT2 in C57Bl/6J mouse striatal membranes assessed as reduction in [3H[-5HT uptake pre-incubated for 10 mins before [3H[-5HT addition and measured after 8 mins2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID1770283Inhibition of [3H]DA uptake at VMAT2 in rat striatal synaptosome at 1 uM incubated for 10 mins followed by [3H]DA addition and measured after 20 mins by TopCount scintillation counting method relative to control2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors.
AID1387462Cytotoxicity in HEK293 cells expressing human VMAT2 assessed as reduction in cell viability at 10 uM incubated for 24 hrs by MTT assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID1387457Displacement of [125I]DOI from human 5HT2A receptor expressed in HEK293 cell membranes2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID1387455Inhibition of human VMAT2 expressed in HEK293 cell membranes assessed as reduction in [3H[-5HT uptake pre-incubated for 10 mins before [3H[-5HT addition and measured after 6 mins2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID1387454Displacement of [3H](+)-syn-Ethyl 1-(2-(2,4-Dioxo-1,2-dihydroquinazolin-3(4H)-yl)ethyl)-4-(4-fluorophenyl)piperidine-3-carboxylate from human VMAT2 expressed in HEK293 cell membranes incubated for 60 mins by scintillation counting method2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID1770284Inhibition of [3H]DA uptake at VMAT2 in rat striatal synaptosome at 0.1 uM incubated for 10 mins followed by [3H]DA addition and measured after 20 mins by TopCount scintillation counting method relative to control2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (93)

TimeframeStudies, This Drug (%)All Drugs %
pre-199060 (64.52)18.7374
1990's20 (21.51)18.2507
2000's5 (5.38)29.6817
2010's5 (5.38)24.3611
2020's3 (3.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.76 (24.57)
Research Supply Index4.58 (2.92)
Research Growth Index5.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (3.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other94 (96.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]